The long-term impact of our therapy is expected to be transformative for ischaemic stroke patients, significantly improving recovery outcomes and quality of life. By focusing on neuron regeneration through neural progenitor cells enhanced with BDNF, our therapy goes beyond standard treatments, which mainly address the acute phase. Successful clinical trials could position our solution as a preferred alternative, reducing the need for long-term rehabilitation and chronic care, leading to fewer hospital readmissions and improved patient independence.

From a societal and economic perspective, better recovery outcomes will reduce the healthcare burden associated with stroke. Patients will be able to return to work sooner, alleviating the financial strain on families and healthcare systems. Our strategy to partner with large pharmaceutical companies post-phase 2 trials ensures that the therapy can be scaled, making it accessible to a wider population, particularly in Spain and across Europe.

Environmental and ethical considerations are also part of our planning. While using genetically modified cells and vectors presents potential environmental risks, we have implemented strict safety protocols in production and disposal to minimise contamination. Ethically, we are working on reimbursement models to ensure that our therapy remains affordable and accessible to all socioeconomic groups.

In summary, our therapy not only offers significant clinical benefits but also contributes to long-term societal, economic, and environmental sustainability.